Drug delivery systems(DDS),based on particulate carriers(primarily composed of lipids or polymers),have demonstrated its superiority in preclinical tumor diagnosis and therapeutic treatment compared with conventional free drug in chemotherapy.Especially,the so-called enhanced permeability and retention(EPR)effect,which means particles of certain size tends to penetrate interstitial tumor vasculature with higher retention time and accumulate more preferentially in tumor tissue than normal tissues,endows the targeted distribution of drug-loaded nanoparticles in vivo and enhances therapeutic efficiency of cancer and other inflammation for parenteral(primarily intravenous)applications.